Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Dorinsky

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
The Lancet. Respiratory Medicine|August 22, 2021
Perplexing mortality data from triple therapy trials in COPD - Author's replyFernando J Martinez, Patrick Darken, Paul Dorinsky, et al.
American Journal of Respiratory and Critical Care Medicine|January 14, 2021
Reply to López-Campos <i>et al.</i> and to Rogliani and CalzettaFernando J Martinez, Patrick Darken, Paul Dorinsky
Respiratory Research|June 29, 2021
Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil countsShigeo Muro, Hisatoshi Sugiura, Patrick Darken, et al.
The New England Journal of Medicine|September 30, 2020
Triple Inhaled Therapy in COPD. ReplyKlaus F Rabe, Fernando J Martinez, Paul Dorinsky
Respiratory Research|August 10, 2021
Corrections to: Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil countsShigeo Muro, Hisatoshi Sugiura, Patrick Darken, et al.
Pharmacoeconomics|October 17, 2002
Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthmaKetan Sheth, Rohit Borker, Amanda Emmett, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 26, 2014
Impact of exhaled nitric oxide measurements on treatment decisions in an asthma specialty clinicCraig LaForce, Elizabeth Brooks, Nancy Herje, et al.
Clinical Pharmacology in Drug Development|June 15, 2018
Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy AdultsAndrea Maes, Paolo DePetrillo, Shahid Siddiqui, et al.
Pulmonary Pharmacology & Therapeutics|May 16, 2018
Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descentPaul Dorinsky, Paolo DePetrillo, Shahid Siddiqui, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|September 3, 2005
Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curvesRohit Borker, Amanda Emmett, Priti Jhingran, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
The Lancet. Respiratory Medicine|August 22, 2021
Perplexing mortality data from triple therapy trials in COPD - Author's replyFernando J Martinez, Patrick Darken, Paul Dorinsky, et al.
American Journal of Respiratory and Critical Care Medicine|January 14, 2021
Reply to López-Campos <i>et al.</i> and to Rogliani and CalzettaFernando J Martinez, Patrick Darken, Paul Dorinsky
Respiratory Research|June 29, 2021
Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil countsShigeo Muro, Hisatoshi Sugiura, Patrick Darken, et al.
The New England Journal of Medicine|September 30, 2020
Triple Inhaled Therapy in COPD. ReplyKlaus F Rabe, Fernando J Martinez, Paul Dorinsky
Respiratory Research|August 10, 2021
Corrections to: Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil countsShigeo Muro, Hisatoshi Sugiura, Patrick Darken, et al.
Pharmacoeconomics|October 17, 2002
Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthmaKetan Sheth, Rohit Borker, Amanda Emmett, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 26, 2014
Impact of exhaled nitric oxide measurements on treatment decisions in an asthma specialty clinicCraig LaForce, Elizabeth Brooks, Nancy Herje, et al.
Clinical Pharmacology in Drug Development|June 15, 2018
Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy AdultsAndrea Maes, Paolo DePetrillo, Shahid Siddiqui, et al.
Pulmonary Pharmacology & Therapeutics|May 16, 2018
Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descentPaul Dorinsky, Paolo DePetrillo, Shahid Siddiqui, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|September 3, 2005
Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curvesRohit Borker, Amanda Emmett, Priti Jhingran, et al.
Pageof 6